Upfront resection versus no resection of the primary tumor in patients with synchronous mCRC – Julius Center Research Program Cancer
Julius Center Research Program Cancer shared a post on LinkedIn: .
“Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer.
Publication and method news flash
The aim of the phase 3 CAIRO4 study that randomized 206 patients since 2012 was to investigate whether the addition of upfront primary tumor resection (PTR) to systemic therapy resulted in a survival benefit in patients with synchronous metastatic colorectal cancer (mCRC) without severe symptoms of their primary tumor.
Using the Max-Combo test as the primary analysis method for comparing survival outcomes between treatment arms in the presence of anticipated non-proportional hazards, the median overall survival in the arm without upfront PTR was 18.3 months (95% CI 16.0-22.2) compared to 20.1 months (95% CI 17.0-25.1) in the upfront PTR arm (p = 0.32).
Upfront PTR added to palliative systemic therapy in patients with synchronous mCRC without severe symptoms of the primary tumor does not result in a survival benefit. This practice should no longer be considered standard of care.
Read the full article in Annals of Oncology.”
